Inebilizumab treatment for autoimmune hepatitis
Treatments studied
Part of Digestive system, Immune system & allergy clinical trials.
This trial tests a new medication called inebilizumab for people with autoimmune hepatitis (a condition where the body's immune system attacks the liver) who haven't responded well to standard treatments or can't tolerate them. The study aims to see if this new drug can help control liver inflammation and reduce the need for high-dose steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–74 years old
- Diagnosed with autoimmune hepatitis confirmed by recent liver biopsy (within 90 days)
- Either tried standard treatments for at least 9 months without good control, or had to stop standard treatments due to side effects
- Elevated liver enzymes (ALT) at screening showing active disease
- Stable doses of current medications for at least 12 weeks before screening
- Willingness to use contraception during treatment and for 6 months after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called belimumab for people with autoimmune hepatitis that is not well controlled. It aims to see if adding belimumab to your current treatment can help reduce liver inflammation.
This test compares two medicines—azathioprine and mycophenolate mofetil (MMF)—to see which is better at putting autoimmune hepatitis into remission without using steroids first. It is for people who have just been diagnosed and haven't started treatment yet.
This study looks at factors that help predict how well people with autoimmune hepatitis respond to treatment. It is for patients who are newly diagnosed or have not had treatment for at least 3 months, and who have had a liver biopsy to confirm the diagnosis.
This trial tests a drug called Siplizumab in people with autoimmune hepatitis or primary sclerosing cholangitis who are on the liver transplant waitlist. It aims to see if the drug can help manage their condition before and after transplant.
This study tests if an investigational drug called inebilizumab is safe and helpful for children with generalized myasthenia gravis (gMG). It is for children ages 2 to 17 who have certain antibodies or typical symptoms of gMG and are already on stable treatment.
This Phase 2 study tests inebilizumab in people with NMDA receptor encephalitis, an immune-related brain condition. It looks to see if adding this treatment after starting steroids (and possibly other first treatments) improves recovery and safety.
Hear when a new Autoimmune Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.